Development of sensor-equipped smart guidewires through the acquisition of Pathways
First written in FY2021-Q3. 1 of 4 entries say "Achieved", first in FY2021. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025WorsenedAnnual report
「With respect to goodwill and other intangible assets related to the 4 companies 朝日サージカルロボティクス株式会社, Pathways Medical Corporation, Rev1. Engineering, Inc. and Asahi Medical Technologies, Inc., the company recognized impairment losses because, after taking into account the recent business environment and future business plans, it was no longer expected to recover its investment due to declining profitability and other factors.」
Recognized an impairment loss of ¥3,636 million on acquisition-related assets of Pathways Medical Corporation due to lower expected recoverability. - FY2023-Q2Finalized the purchase price allocation for Pathways.Annual report
「The business combination with Pathways Medical Corporation conducted on 1 July 2021 was accounted for provisionally during the second quarter of the previous fiscal year and finalized during the third quarter of the previous fiscal year.」
The purchase price allocation for the Pathways acquisition was finalized, increasing goodwill from the provisional ¥101 million to ¥238 million. - FY2021AchievedAnnual report
「At a Board of Directors meeting held on 12 April 2021, the company resolved to acquire shares in Pathways Medical Corporation and make it a subsidiary, and acquired all shares on 1 July 2021.」
Completed the acquisition of all shares in Pathways Medical Corporation on 1 July 2021, incorporating its thin-film electrical wiring technology. - FY2021-Q3First statedAnnual report
「The company entered into a basic agreement to consider acquiring 100% of Pathways Medical’s shares for the purpose of applying the technology held by Pathways Medical to the stroke smart guidewire being jointly developed with SENSOME in France, among other objectives.」
Entered into a basic agreement to consider acquiring 100% of Pathways Medical Corporation, which owns thin-film electrical conductor technology. The purpose is to strengthen development of stroke smart guidewires combining SENSOME’s sensor technology with the company’s own guidewire technology, as well as guidewires and catheters equipped with sensors. The share acquisition was scheduled for 1 July 2021, with an upfront payment of ¥2,444 million and potential milestone payments of up to ¥744 million by July 2023.